Want to see GB:AREC full AI Analyst Report?
AREC Stock Chart & Stats
85.00 p
-0.75 p(-1.01%)
At close: 4:00 PM EST
85.00 p
-0.75 p(-1.01%)
Day’s Range― - ―
52-Week Range56.00 p - 100.00 p
Previous CloseN/A
Volume5.49K
Average Volume (3M)40.10K
Market Cap
£23.03M
Enterprise Value14.71 p
Total Cash (Recent Filing)£6.13M
Total Debt (Recent Filing)£98.00K
Price to Earnings (P/E)34.7
Beta0.58
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding37,756,600
10 Day Avg. Volume67,644
30 Day Avg. Volume40,099
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)4.71
Price to Sales (P/S)17.73
P/FCF Ratio-12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)£900.00K
Bulls Say, Bears Say
Bulls Say
Proprietary Formulation Platform & Partnership ModelArecor's Arestat platform and its stated business model of partnering and licensing create a durable, capital-efficient route to revenue: formulation IP can be licensed to pharma partners, generating upfront, R&D and milestone payments and royalties without requiring full commercial infrastructure, sustaining long-term cash inflows if partners advance programs.
Low Leverage Balance SheetVery low debt provides financial flexibility for a development-stage biotech: limited interest burden and borrowing covenants reduce insolvency risk, improve negotiating power in partnerships or licensing deals, and allow management to pursue R&D and collaborations without immediate debt servicing constraints over the medium term.
Meaningful Reduction In Cash Burn In 2025Narrowing free cash flow losses indicates management has either cut costs, advanced lower-cost programs, or secured non-dilutive partner funding; this trend, if sustained, lengthens runway and reduces near-term financing needs, making execution on partnerships or selective development milestones more feasible over coming quarters.
Bears Say
Revenue Volatility And Sharp 2025 DeclineA ~66% revenue decline in 2025 after prior growth highlights structurally unpredictable top-line performance, reflecting reliance on lumpy partner/license payments or one-off events. Persistent revenue volatility undermines forecasting, weakens recurring cash flow visibility, and raises execution risk for sustaining R&D and commercial activities long-term.
Consistent Operating LossesSustained negative operating results mean product programs and platform commercialization have yet to generate operating profitability; this forces continued dependence on financing, dilutive equity raises or partner deals to fund R&D, and constrains ability to reinvest in pipeline expansion or scale commercial capabilities over multiple years.
Weak Cash Generation; Reliance On External FundingPersistent negative operating cash flow signals structural inability to self-fund development; ongoing reliance on external financing or partnerships increases dilution and timing risk. If partner deals or fundraising slow, the company may face constrained investment in key reformulation programs and delayed milestone realizations over the medium term.
Arecor Therapeutics PLC News
AREC FAQ
What was Arecor Therapeutics PLC’s price range in the past 12 months?
Arecor Therapeutics PLC lowest share price was 56.00 p and its highest was 100.00 p in the past 12 months.
What is Arecor Therapeutics PLC’s market cap?
Arecor Therapeutics PLC’s market cap is £23.03M.
When is Arecor Therapeutics PLC’s upcoming earnings report date?
Arecor Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 48 days.
How were Arecor Therapeutics PLC’s earnings last quarter?
Currently, no data Available
Is Arecor Therapeutics PLC overvalued?
According to Wall Street analysts Arecor Therapeutics PLC’s price is currently Overvalued.
Does Arecor Therapeutics PLC pay dividends?
Arecor Therapeutics PLC does not currently pay dividends.
What is Arecor Therapeutics PLC’s EPS estimate?
Arecor Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arecor Therapeutics PLC have?
Arecor Therapeutics PLC has 37,756,600 shares outstanding.
What happened to Arecor Therapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arecor Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AREC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arecor Therapeutics PLC
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioMedica
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―